Cite
Zimmer L, Livingstone E, Krackhardt A, et al. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. Eur J Cancer. 2021;158:72-84doi: 10.1016/j.ejca.2021.09.011.
Zimmer, L., Livingstone, E., Krackhardt, A., Schultz, E. S., Göppner, D., Assaf, C., Trebing, D., Stelter, K., Windemuth-Kieselbach, C., Ugurel, S., & Schadendorf, D. (2021). Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. European journal of cancer (Oxford, England : 1990), 15872-84. https://doi.org/10.1016/j.ejca.2021.09.011
Zimmer, Lisa, et al. "Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF." European journal of cancer (Oxford, England : 1990) vol. 158 (2021): 72-84. doi: https://doi.org/10.1016/j.ejca.2021.09.011
Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. Eur J Cancer. 2021 Oct 13;158:72-84. doi: 10.1016/j.ejca.2021.09.011. Epub 2021 Oct 13. PMID: 34655839.
Copy
Download .nbib